Showing posts with label Genentech. Show all posts
Showing posts with label Genentech. Show all posts
Wednesday, January 28, 2009
Biotech Firm Praised
RBC Capital Markets has an outperform rating on Genentech(DNA).Its price target for the stock is 100 dollars.Lazard Capital Markets says Genentech is best in class,producing lifesaving drugs for double digit earnings.
Wednesday, October 22, 2008
Genentech Reports
Genentech(DNA) reported earnings of 0.81 cents a share versus an estimate of 0.88.Revenue was 3.41 billion dollars versus an estimate of 3.36 billion.Its forecast for Q4 is 3.40-3.45 billion.Cowan and Company upgraded the stock from neutral to outperform.
Subscribe to:
Posts (Atom)